Akari Therapeutics Plc RSI
What is the RSI of Akari Therapeutics Plc?
The RSI of Akari Therapeutics Plc is 47.45
What is the definition of RSI?
The relative strength index (RSI 14) is a momentum indicator that compares the magnitude of gains and losses over a specified time period to measure speed and change of price movements of a security.
14-day period
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI of companies in the Health Care sector on NASDAQ compared to Akari Therapeutics Plc
What does Akari Therapeutics Plc do?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Companies with rsi similar to Akari Therapeutics Plc
- UBS ETF (CH) - SBI Domestic Government 1-3 has RSI of 47.43
- Inspiration Healthcare plc has RSI of 47.43
- Kerr Mines has RSI of 47.44
- Firsthand Technology Value Fund Inc has RSI of 47.44
- Rogers Communications has RSI of 47.44
- St. Augustine Gold and Copper has RSI of 47.44
- Akari Therapeutics Plc has RSI of 47.45
- Ultra Petroleum has RSI of 47.46
- Gett Gold Inc has RSI of 47.46
- Zacatecas Silver has RSI of 47.46
- CK Infrastructure has RSI of 47.46
- Siemens AG has RSI of 47.46
- Jia limited has RSI of 47.46